In recent years, mutation profiles of NSCLC have been clarified, with frequent mutations identified in driver genes such as epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2) (8, 9). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.